Kurimoto E - Search Results

1

Retinoic acid receptor stimulation protects midbrain dopaminergic neurons from inflammatory degeneration via BDNF-mediated signaling.

Katsuki H, Kurimoto E, Takemori S, Kurauchi Y, Hisatsune A, Isohama Y, Izumi Y, Kume T, Shudo K, Akaike A. Katsuki H, et al. Among authors: kurimoto e. J Neurochem. 2009 Jul;110(2):707-18. doi: 10.1111/j.1471-4159.2009.06171.x. Epub 2009 May 15. J Neurochem. 2009. PMID: 19457078 Free article.

2

Resveratrol protects dopaminergic neurons in midbrain slice culture from multiple insults.

Okawara M, Katsuki H, Kurimoto E, Shibata H, Kume T, Akaike A. Okawara M, et al. Among authors: kurimoto e. Biochem Pharmacol. 2007 Feb 15;73(4):550-60. doi: 10.1016/j.bcp.2006.11.003. Epub 2006 Nov 9. Biochem Pharmacol. 2007. PMID: 17147953 Free article.

3

FTBMT, a Novel and Selective GPR52 Agonist, Demonstrates Antipsychotic-Like and Procognitive Effects in Rodents, Revealing a Potential Therapeutic Agent for Schizophrenia.

Nishiyama K, Suzuki H, Harasawa T, Suzuki N, Kurimoto E, Kawai T, Maruyama M, Komatsu H, Sakuma K, Shimizu Y, Shimojo M. Nishiyama K, et al. Among authors: kurimoto e. J Pharmacol Exp Ther. 2017 Nov;363(2):253-264. doi: 10.1124/jpet.117.242925. Epub 2017 Aug 29. J Pharmacol Exp Ther. 2017. PMID: 28851764

4

Design, synthesis, and pharmacological evaluation of 4-azolyl-benzamide derivatives as novel GPR52 agonists.

Tokumaru K, Ito Y, Nomura I, Nakahata T, Shimizu Y, Kurimoto E, Aoyama K, Aso K. Tokumaru K, et al. Among authors: kurimoto e. Bioorg Med Chem. 2017 Jun 15;25(12):3098-3115. doi: 10.1016/j.bmc.2017.03.064. Epub 2017 Apr 1. Bioorg Med Chem. 2017. PMID: 28433511

5

TAK-071, a novel M₁ positive allosteric modulator with low cooperativity, improves cognitive function in rodents with few cholinergic side effects.

Sako Y, Kurimoto E, Mandai T, Suzuki A, Tanaka M, Suzuki M, Shimizu Y, Yamada M, Kimura H. Sako Y, et al. Among authors: kurimoto e. Neuropsychopharmacology. 2019 Apr;44(5):950-960. doi: 10.1038/s41386-018-0168-8. Epub 2018 Aug 1. Neuropsychopharmacology. 2019. PMID: 30089885 Free PMC article.

6

T-495, a novel low cooperative M₁ receptor positive allosteric modulator, improves memory deficits associated with cholinergic dysfunction and is characterized by low gastrointestinal side effect risk.

Mandai T, Sako Y, Kurimoto E, Shimizu Y, Nakamura M, Fushimi M, Maeda R, Miyamoto M, Kimura H. Mandai T, et al. Among authors: kurimoto e. Pharmacol Res Perspect. 2020 Feb;8(1):e00560. doi: 10.1002/prp2.560. Pharmacol Res Perspect. 2020. PMID: 31990455 Free PMC article.

7

Therapeutic potential of TAK-071, a muscarinic M₁ receptor positive allosteric modulator with low cooperativity, for the treatment of cognitive deficits and negative symptoms associated with schizophrenia.

Kurimoto E, Yamada R, Hirakawa T, Kimura H. Kurimoto E, et al. Neurosci Lett. 2021 Nov 1;764:136240. doi: 10.1016/j.neulet.2021.136240. Epub 2021 Sep 10. Neurosci Lett. 2021. PMID: 34509568 Free article.

8

In Vivo Pharmacological Comparison of TAK-071, a Positive Allosteric Modulator of Muscarinic M₁ Receptor, and Xanomeline, an Agonist of Muscarinic M₁/M₄ Receptor, in Rodents.

Mandai T, Kasahara M, Kurimoto E, Tanaka M, Suzuki M, Nakatani A, Kimura H. Mandai T, et al. Among authors: kurimoto e. Neuroscience. 2019 Aug 21;414:60-76. doi: 10.1016/j.neuroscience.2019.07.003. Epub 2019 Jul 9. Neuroscience. 2019. PMID: 31299348

9

TAK-071, a muscarinic M1 receptor positive allosteric modulator, attenuates scopolamine-induced quantitative electroencephalogram power spectral changes in cynomolgus monkeys.

Kurimoto E, Nakashima M, Kimura H, Suzuki M. Kurimoto E, et al. PLoS One. 2019 Mar 11;14(3):e0207969. doi: 10.1371/journal.pone.0207969. eCollection 2019. PLoS One. 2019. PMID: 30856192 Free PMC article.

10

An Approach to Discovering Novel Muscarinic M₁ Receptor Positive Allosteric Modulators with Potent Cognitive Improvement and Minimized Gastrointestinal Dysfunction.

Kurimoto E, Matsuda S, Shimizu Y, Sako Y, Mandai T, Sugimoto T, Sakamoto H, Kimura H. Kurimoto E, et al. J Pharmacol Exp Ther. 2018 Jan;364(1):28-37. doi: 10.1124/jpet.117.243774. Epub 2017 Oct 12. J Pharmacol Exp Ther. 2018. PMID: 29025977

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

88 results

Search Page